Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

Efficacy and safety of daptomycin in patients with renal impairment: a multicenter retrospective analysis.

Kullar R, McClellan I, Geriak M, Sakoulas G.

Pharmacotherapy. 2014 Jun;34(6):582-9. doi: 10.1002/phar.1413. Epub 2014 Mar 21.

PMID:
24658897
2.

High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.

Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ.

Pharmacotherapy. 2011 Jun;31(6):527-36. doi: 10.1592/phco.31.6.527.

PMID:
21923436
3.

Safety of daptomycin in patients receiving hemodialysis.

Mueller BA, Crompton JA, Donovan BJ, Yankalev S, Lamp KC.

Pharmacotherapy. 2011 Jul;31(7):665-72. doi: 10.1592/phco.31.7.665.

4.

Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients.

Gallagher JC, Perez ME, Marino EA, LoCastro LG, Abrardo LA, MacDougall C.

Pharmacotherapy. 2009 Jul;29(7):792-9. doi: 10.1592/phco.29.7.792.

PMID:
19558253
5.

Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients.

Lai CC, Sheng WH, Wang JT, Cheng A, Chuang YC, Chen YC, Chang SC.

BMC Infect Dis. 2013 Feb 4;13:66. doi: 10.1186/1471-2334-13-66.

6.

Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment.

Moise PA, Amodio-Groton M, Rashid M, Lamp KC, Hoffman-Roberts HL, Sakoulas G, Yoon MJ, Schweitzer S, Rastogi A.

Antimicrob Agents Chemother. 2013 Mar;57(3):1192-200. doi: 10.1128/AAC.02192-12. Epub 2012 Dec 17.

7.

Brazilian experience in EU-CORE: daptomycin registry and treatment of serious Gram-positive infections.

Timerman A, Brites C, Bicudo E, Grinbaum RS, Costa Filho R, Carrilho CD, Bichels A, Barreto T.

Braz J Infect Dis. 2013 Nov-Dec;17(6):647-53. doi: 10.1016/j.bjid.2013.03.005. Epub 2013 Jul 31.

8.

Multicenter study of high-dose daptomycin for treatment of enterococcal infections.

Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ.

Antimicrob Agents Chemother. 2013 Sep;57(9):4190-6. doi: 10.1128/AAC.00526-13. Epub 2013 Jun 17.

9.

Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.

Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC.

Ann Pharmacother. 2009 Jul;43(7):1211-9. doi: 10.1345/aph.1M085. Epub 2009 Jul 7.

PMID:
19584384
10.

Prospective, non-comparative study of daptomycin for the treatment of superficial and deep incisional surgical site infections.

Knapp AG, Kamepalli RK, Martone WJ, Yankelev S.

Surg Infect (Larchmt). 2011 Apr;12(2):113-8. doi: 10.1089/sur.2008.106. Epub 2011 Feb 24.

PMID:
21348765
11.

Daptomycin therapy for invasive Gram-positive bacterial infections in children.

Ardura MI, Mejías A, Katz KS, Revell P, McCracken GH Jr, Sánchez PJ.

Pediatr Infect Dis J. 2007 Dec;26(12):1128-32.

PMID:
18043450
13.

[Daptomycin in the treatment of Gram-positive infections in patients with chronic renal failure].

Sarriá Cepeda C.

Enferm Infecc Microbiol Clin. 2012 Feb;30 Suppl 1:38-42. doi: 10.1016/S0213-005X(12)70070-8. Spanish.

PMID:
22541974
14.

Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States.

Bookstaver PB, Bland CM, Qureshi ZP, Faulkner-Fennell CM, Sheldon MA, Caulder CR, Hartis C; SERGE-45 Investigators.

Pharmacotherapy. 2013 Dec;33(12):1322-30. doi: 10.1002/phar.1298. Epub 2013 May 26.

PMID:
23712701
15.

Evaluation of a daptomycin dose-optimization protocol.

Tran TT, Palmer HR, Weston J, Hirsch EB, Shah DN, Cottreau J, Tam VH, Garey KW.

Am J Health Syst Pharm. 2012 Jun 1;69(11):979-84. doi: 10.2146/ajhp110279.

PMID:
22610031
16.

Daptomycin experience in critical care patients: results from a registry.

Brown JE, Fominaya C, Christensen KJ, McConnell SA, Lamp KC.

Ann Pharmacother. 2012 Apr;46(4):495-502. doi: 10.1345/aph.1Q490. Epub 2012 Mar 27.

PMID:
22454446
17.

Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program.

Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C, Wehbeh W, Urban CM, Segal-Maurer S.

Clin Infect Dis. 2009 Jul 15;49(2):177-80. doi: 10.1086/600039.

PMID:
19500039
18.

Daptomycin experience in patients with human immunodeficiency virus and resistant gram-positive infections.

Slim J, Jimenez H, Culshaw D, Patel H, Lamp KC.

J Int Assoc Provid AIDS Care. 2015 May-Jun;14(3):202-6. doi: 10.1177/2325957414553840. Epub 2014 Oct 15.

PMID:
25320146
19.

Daptomycin in the treatment of bacteremia.

Sakoulas G, Golan Y, Lamp KC, Friedrich LV, Russo R.

Am J Med. 2007 Oct;120(10 Suppl 1):S21-7.

PMID:
17904947
20.

[The efficacy and safety of daptomycin for the treatment of Gram-positive bacterial infections in Chinese population].

Zhang L, Li J, Wan X, Shen J, Liu H, Gao H, Liu Z, Wang A.

Zhonghua Nei Ke Za Zhi. 2015 Jun;54(6):496-500. Chinese.

PMID:
26359009

Supplemental Content

Support Center